Multi-matrix metabolome and microbiome profiling in diarrhea-predominant irritable bowel syndrome and ulcerative colitis in remission with IBS-like symptoms
Inflammatory Bowel Diseases · 04.11.2026
DOI: 10.1093/ibd/izag243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 04.11.2026. Verfasst von Guorong Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the National Key Research and Development Program, China Health and Medical Development Foundation.
Abstract (Originalsprache)
Background
Irritable bowel syndrome (IBS)-like symptoms frequently persist in patients with ulcerative colitis (UC) in remission. Whether UC in remission with IBS-like symptoms (UCR-IBS) represents functional overlap with diarrhea-predominant IBS (IBS-D) or a distinct metabolic phenotype remains unclear.
Methods
In this exploratory cross-sectional study, 39 patients with IBS-D, 21 with UCR-IBS, and 35 healthy controls were enrolled. Serum, urine, fecal, and colonic mucosal samples were collected. Untargeted metabolomics, targeted tryptophan profiling, fecal 16S ribosomal RNA gene sequencing, predicted microbial functional profiling, and microbe-metabolite association analyses were performed.
Results
Tryptophan-related metabolism was altered in both patient groups, but the patterns differed across biological matrices. Compared with IBS-D, UCR-IBS showed higher serum N-formylkynurenine (NFK) concentrations, and fecal findings suggested reduced concentrations of microbiota-associated indole metabolites. Microbiome differences were modest, but predicted nicotinate/nicotinamide metabolism was enriched in UCR-IBS. Exploratory network analysis identified associations between tryptophan-related metabolites and selected bacterial genera in each group.
Conclusions
Multi-matrix profiling shows tryptophan-related metabolic differences between mesalazine-treated UCR-IBS and IBS-D, highlighting higher serum NFK concentrations in UCR-IBS. These findings provide a basis for investigating host-microbiota metabolic relationships across systemic and intestinal compartments during UC remission. This trial was registered in the Chinese Clinical Trial Registry (ChiCTR; https://www.chictr.org.cn/) under registration number ChiCTR2200060224.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- Department of Gastroenterology, China-Japan Friendship Hospital, Beijing, China.
- Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food Poisoning, Beijing Center for Disease Prevention and Control, Beijing, China.
- School of Food and Bioengineering, Xihua University, Chengdu, China.
ORCID-Profile: Guorong Chen, Yanli Zhang
Förderung
- the National Key Research and Development Program
- China Health and Medical Development Foundation
Zitieren
APA
Chen, G., Du, S., Li, H., Wang, H., Zhu, H., Zhang, Q., Yang, R., Wu, X., Shao, B., & Zhang, Y. (2026). Multi-matrix metabolome and microbiome profiling in diarrhea-predominant irritable bowel syndrome and ulcerative colitis in remission with IBS-like symptoms. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag243
Vancouver
Chen G, Du S, Li H, Wang H, Zhu H, Zhang Q, et al. Multi-matrix metabolome and microbiome profiling in diarrhea-predominant irritable bowel syndrome and ulcerative colitis in remission with IBS-like symptoms. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag243
BibTeX
@article{Chen2026,
author = {Chen, Guorong and Du, Shiyu and Li, Hui and Wang, Huifen and Zhu, Huiting and Zhang, Qin and Yang, Runhui and Wu, Xuan and Shao, Bing and Zhang, Yanli},
title = {Multi-matrix metabolome and microbiome profiling in diarrhea-predominant irritable bowel syndrome and ulcerative colitis in remission with IBS-like symptoms},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izag243}
}
EUVIMED